## Medical Management of Adrenocortical Carcinoma with Cushing Syndrome **Key Point:** Mitotane is the only drug with proven adrenolytic (tumor-destroying) activity and is the first-line medical agent for unresectable adrenocortical carcinoma causing Cushing syndrome. ### Mechanism of Action Mitotane (o,p'-DDD) is an adrenolytic agent that: 1. Causes direct cytotoxic damage to adrenocortical cells (both normal and malignant) 2. Inhibits multiple enzymes in steroid synthesis (11β-hydroxylase, 17α-hydroxylase, P450scc) 3. Induces apoptosis in adrenocortical tissue 4. Has both cytostatic and cytotoxic effects on adrenocortical carcinoma cells ### Pharmacokinetics & Dosing | Parameter | Value | |-----------|-------| | **Half-life** | 18–159 days (highly variable) | | **Time to steady state** | 8–12 weeks | | **Therapeutic plasma level** | 14–20 mg/L (some use up to 20–30 mg/L) | | **Starting dose** | 2–3 g/day in divided doses | | **Target dose** | 8–10 g/day (titrated based on levels and tolerance) | | **Monitoring** | Plasma mitotane levels, cortisol, ACTH, liver/renal function | **High-Yield:** Mitotane is the ONLY agent with anti-tumor activity in adrenocortical carcinoma. It is not used for benign Cushing syndrome (pituitary or adrenal adenoma). ### Clinical Efficacy in Adrenocortical Carcinoma - **Cortisol control:** 60–80% of patients achieve normal cortisol levels - **Tumor response:** 30–35% achieve partial or complete radiologic response - **Survival benefit:** Improves recurrence-free and overall survival when used adjuvantly post-resection - **Onset:** Slow (7–14 days for cortisol effect; weeks to months for tumor response) ### Monitoring & Side Effects **Frequent Adverse Effects:** - Gastrointestinal: nausea, vomiting, diarrhea (40–80% of patients) - Neurologic: ataxia, vertigo, confusion (10–40%) - Hyperlipidemia (50%) - Hepatotoxicity (mild elevation of transaminases) **Management:** - Antiemetics (5-HT3 antagonists, metoclopramide) - Dose reduction if intolerable - Monitor lipid panel and liver function monthly initially - Glucocorticoid and mineralocorticoid replacement (due to adrenolysis) **Clinical Pearl:** Because mitotane causes adrenolysis, patients require long-term glucocorticoid (hydrocortisone or dexamethasone) and often mineralocorticoid (fludrocortisone) replacement. Replacement must be started before or concurrent with mitotane to prevent acute adrenal crisis. ### Why Mitotane Over Other Agents in This Scenario ```mermaid flowchart TD A[Adrenocortical Carcinoma<br/>with Cushing Syndrome]:::outcome A --> B{Resectable?}:::decision B -->|Yes| C[Surgical resection<br/>+ adjuvant mitotane]:::action B -->|No| D[Unresectable/Metastatic]:::urgent D --> E[Mitotane<br/>Primary agent]:::action E --> F[Cortisol control +<br/>Anti-tumor effect]:::outcome E --> G[Add ketoconazole or<br/>metyrapone if needed]:::action G --> H[Combination therapy<br/>for refractory cases]:::outcome ``` **Comparison with Alternatives:** | Agent | Role in ACC | Onset | Anti-tumor | Notes | |-------|-------------|-------|-----------|-------| | **Mitotane** | First-line | 7–14 days | Yes | Only agent with proven tumor activity | | **Ketoconazole** | Second-line | 3–5 days | No | Rapid cortisol control; used as adjunct | | **Metyrapone** | Second-line | 24–48 h | No | Rapid onset; used as adjunct or bridge | | **Etomidate** | ICU only | Minutes | No | For life-threatening hypercortisolism in ICU; IV only | **High-Yield:** In unresectable adrenocortical carcinoma, mitotane is monotherapy. If cortisol control is inadequate, ketoconazole or metyrapone is added as a second agent—never used alone. [cite:Harrison 21e Ch 375; Endocrine Society Clinical Practice Guidelines on Adrenocortical Carcinoma]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.